CIP epidemiology and risk factors: The incidence of CIP is 3–5%, but the mortality rate is 10–17%, accounting for 35% of deaths associated with PD-1 and PD-L1 inhibitors (28, 29). Here, CD274 is linked to hereditary sensory and autonomic neuropathy.